Cellebrite DI (NASDAQ:CLBT) CFO David Barter Sells 41,734 Shares

Cellebrite DI Ltd. (NASDAQ:CLBT) CFO David Barter sold 41,734 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cellebrite DI Trading Down 2.3%

Shares of NASDAQ CLBT opened at $16.13 on Friday. The firm has a fifty day simple moving average of $13.70 and a two-hundred day simple moving average of $14.52. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The firm has a market capitalization of $4.02 billion, a PE ratio of 57.61, a price-to-earnings-growth ratio of 2.05 and a beta of 1.17.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors have recently made changes to their positions in the company. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI in the 3rd quarter worth approximately $55,999,000. Granahan Investment Management LLC raised its stake in shares of Cellebrite DI by 1,108.5% in the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after purchasing an additional 2,411,726 shares during the last quarter. Capital International Investors bought a new position in shares of Cellebrite DI during the fourth quarter valued at $41,073,000. Invesco Ltd. boosted its position in shares of Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after buying an additional 2,054,644 shares during the last quarter. Finally, Weiss Asset Management LP increased its holdings in Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CLBT shares. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson assumed coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and a consensus price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.